No headlines found.
A decade of profitability provides foundation for CLINUVEL's U.S. expansion
Globe Newswire (Thu, 27-Aug 1:42 AM ET)
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
Globe Newswire (Thu, 23-Jul 12:10 AM ET)
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
Clinuvel Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol CUVL.
As of September 9, 2026, CUVL stock price declined to $5.94 with 13,083 million shares trading.
CUVL has a market cap of $299.54 million. This is considered a Small Cap stock.
CUVL support price is $5.66 and resistance is $6.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUVL shares will trade within this expected range on the day.
